Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Hope in the Fight Against Ovarian CancerOvarian cancer, particularly its most common and lethal form—high-grade serous ...

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data ...

Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...

Please provide your email address to receive an email when new articles are posted on . In this video, Ursula A. Matulonis, MD, discusses a study assessing letrozole alone compared with standard ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

In the field of gynecologic cancer, low-grade serous ovarian cancer (LGSOC) has been poorly understood and underinvestigated until recently. Similarly, understanding of the distinct properties and ...